Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10090707 | 0.85 | KMT2A (0.74) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL852839 | 0.85 | KMT2A (1.00) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL880276 | 0.85 | LMNA (1.00) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL10280720 | 0.85 | KMT2A (0.74) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL853892 | 0.82 | KMT2A (0.69) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL12162833 | 0.82 | KMT2A (0.69) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL10280723 | 0.81 | KDM4E (0.56) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL880347 | 0.80 | LMNA (1.00) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL880456 | 0.78 | KMT2A (0.64) | KMT2ANPC1MEN1LMNARAB9A | |
| SCHEMBL10280292 | 0.78 | LMNA (0.75) | KMT2ANPC1MEN1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289022-A1 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | KMT2A 1570/4885NPC1 2064/4885MEN1 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.